An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma.
James M. G. Larkin
No relevant relationships to disclose
Paola Queirolo
Consultant or Advisory Role - Roche
Ana M Arance
Consultant or Advisory Role - Roche
Honoraria - Roche
Michael Paul Brown
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche
Research Funding - Roche
Axel Hauschild
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Michele Del Vecchio
Consultant or Advisory Role - Merck/Schering-Plough
Research Funding - Celgene; Novartis; Roche
Grant A. McArthur
Consultant or Advisory Role - Plexxikon; Roche/Genentech
Bart Neyns
No relevant relationships to disclose
Jürgen C. Becker
Consultant or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Novartis; Roche
Honoraria - Bristol-Myers Squibb; LEO Pharma; Roche
Research Funding - Medarex
Other Remuneration - Bristol-Myers Squibb; Roche
Johan Hansson
Research Funding - Roche
David Hogg
Consultant or Advisory Role - Roche
Honoraria - Roche
Paolo Antonio Ascierto
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Roche/Genentech
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Roche/Genentech
Carmen Loquai
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Roche
Honoraria - Bristol-Myers Squibb; Roche
Other Remuneration - Bristol-Myers Squibb; LEO Pharma; Roche
Enrique Espinosa
No relevant relationships to disclose
Claus Garbe
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Poulam M Patel
Consultant or Advisory Role - Roche
Jacob Schachter
No relevant relationships to disclose
Lada Mitchell
Employment or Leadership Position - Roche
Maria Luisa Veronese
Employment or Leadership Position - Roche
Christian U. Blank
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Roche
Research Funding - Bristol-Myers Squibb; MedImmune; Novartis